Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Consun Pharmaceutical Group Ltd. ( (HK:1681) ).
Consun Pharmaceutical Group reported a solid set of annual results for the year ended 31 December 2025, with revenue rising 15.2% to RMB3.42 billion and gross profit improving as cost of sales grew more slowly than topline. Net profit attributable to equity shareholders climbed 18.4% to RMB1.08 billion, while basic earnings per share increased to RMB1.27, underscoring improved operating leverage and profitability.
The company also reduced finance costs significantly and maintained profit growth despite higher distribution and administrative expenses, suggesting continued investment in market expansion and operations. The board proposed a final dividend of HKD0.40 per share, signaling confidence in the group’s cash generation and offering a tangible return to shareholders alongside the earnings growth.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$19.50 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
More about Consun Pharmaceutical Group Ltd.
Consun Pharmaceutical Group Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the pharmaceutical industry. The group develops and sells prescription drugs and related pharmaceutical products, generating revenue primarily from the sale of its medicines in mainland China and other markets.
Average Trading Volume: 1,749,899
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.07B
For detailed information about 1681 stock, go to TipRanks’ Stock Analysis page.